Tommy G. Thompson Sells 2,500 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Down 1.0 %

NASDAQ:UTHR traded down $3.13 during midday trading on Tuesday, reaching $316.73. The stock had a trading volume of 345,532 shares, compared to its average volume of 446,533. The stock has a market cap of $14.22 billion, a P/E ratio of 13.91, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82. The firm has a fifty day simple moving average of $344.24 and a two-hundred day simple moving average of $356.84.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the firm posted $4.36 EPS. On average, sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics during the 4th quarter worth $25,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics in the third quarter valued at about $33,000. Dunhill Financial LLC boosted its holdings in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after buying an additional 50 shares in the last quarter. State of Wyoming acquired a new position in United Therapeutics during the fourth quarter worth about $62,000. Finally, Millstone Evans Group LLC purchased a new position in United Therapeutics in the fourth quarter valued at about $67,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.